Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Author(s) -
Amit C. Nathwani,
Edward G. D. Tuddenham,
Savita Rangarajan,
Cecilia Rosales,
Jenny McIntosh,
David C. Linch,
Pratima Chowdary,
Anne Riddell,
Arnulfo Pie,
Chris F. Harrington,
James O’Beirne,
Keith Smith,
John Pasi,
Bertil Glader,
Pradip K. Rustagi,
Catherine Y. Ng,
Mark A. Kay,
Junfang Zhou,
Yunyu Spence,
Christopher L. Morton,
James A. Allay,
John B. Coleman,
Susan Sleep,
John M. Cunningham,
Deo Kumar Srivastava,
Etiena BasnerTschakarjan,
Federico Mingozzi,
Katherine A. High,
John T. Gray,
Ulrike M. Reiss,
Arthur W. Nienhuis,
Andrew M. Davidoff
Publication year - 2011
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1108046
Subject(s) - medicine , genetic enhancement , asymptomatic , factor ix , vector (molecular biology) , virus , viral vector , adeno associated virus , transgene , adenoviridae , virology , gastroenterology , immunology , gene , biology , recombinant dna , biochemistry
Hemophilia B, an X-linked disorder, is ideally suited for gene therapy. We investigated the use of a new gene therapy in patients with the disorder.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom